Myeloproliferative Syndrome - A Diagnosis on the Border Between Medical Specialties

1 Zinzani P.L. The many faces of marginal zone lymphoma. ASH Educ Progr B. 2012;2012(1):426–432. Search in Google Scholar

2 Lenglet J., Traullé C., Mounier N., Benet C., Munoz-Bongrand N., Amorin S. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leuk Lymphoma. 2013;55:1854–1860. Search in Google Scholar

3 Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H. In: World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al., editors. International Agency for Research on Cancer (IARC); Lyon: 2008. International Agency for Research on Cancer (IARC). 422 p. Search in Google Scholar

4 Behdad A., Bailey N.G. Diagnosis of splenic B-cell lymphomas in the bone marrow: a review of histopathologic, immunophenotypic, and genetic findings. Arch Pathol Lab Med. 2014;138(10): 1295–1301. Search in Google Scholar

5 Traverse-Glehen A., Baseggio L., Salles G., Felman P., Berger F. Splenic marginal zone B-cell lymphoma: a distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification. Curr Opin Oncol. 2011;23(5):441–448. Search in Google Scholar

6 Matutes E., Oscier D., Montalban C., Berger F., Callet-Bauchu E., Dogan A. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22(3):487–495. Search in Google Scholar

7 Moreau E.J., Matutes E., A'Hern R.P., Morilla A.M., Morilla R.M., Owusu-Ankomah K.A. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8(CD79b) Am J Clin Pathol. 1997;108(4):378–382. Search in Google Scholar

8 Chacón J.I., Mollejo M., Muñoz E., Algara P., Mateo M., Lopez L. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002;100(5):1648–1654. Search in Google Scholar

9 Iannitto E., Ambrosetti A., Ammatuna E., Colosio M., Florena A.M., Tripodo C. Splenic marginal zone lymphoma with or without villous lymphocytes. Cancer. 2004;101(9):2050–2057. Search in Google Scholar

10 Kalpadakis C., Pangalis G.A., Vassilakopoulos T.P., Sachanas S., Angelopoulou M.K. Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned? Leuk Lymphoma. 2014;55(7):1463–1470. Search in Google Scholar

11 Arcaini L., Rossi D., Paulli M. Splenic marginal zone lymphoma: from genetics to management. Blood. 2016;127(17):2072–2081. Search in Google Scholar

12 Tsimberidou A.M., Catovsky D., Schlette E., O'Brien S., Wierda W.G., Kantarjian H. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006;107(1):125–135. Search in Google Scholar

13 Thieblemont C., Felman P., Berger F., Dumontet C., Arnaud P., Hequet O. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma. 2002;3(1):41–47. Search in Google Scholar

14 Kalpadakis C., Pangalis G.A., Maria K.A., Sachanas S., Kontopidou F.N., Yiakoumis X. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist. 2013;18(2):190–197. Search in Google Scholar

15 Else M., Marín-Niebla A., de la Cruz F., Batty P., Ríos E., Dearden C.E. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol. 2012;159(3):322–328. Search in Google Scholar

16 Kalpadakis C., Pangalis G.A., Dimopoulou M.N., Vassila-kopoulos T.P., Kyrtsonis M-C., Korkolopoulou P. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol. 2007;25(3): 127–131. Search in Google Scholar

17 Bennett M., Yegena S., Chubar E., Schechter G. Rituximab monotherapy in splenic marginal zone lymphoma instead of splenectomy. Br J Haematol. 2010;149(Suppl. 1):45. Search in Google Scholar

18 Dreyling M., Thieblemont C., Gallamini A., Arcaini L., Campo E., Hermine O. Esmo consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24(4):857–877. Search in Google Scholar